Immix Biopharma, Inc.
IMMX· Nasdaq
Released May 7, 2026, after the close
10-Q filed May 7, 2026, 37 days after period end · 0001493152-26-021764
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$10.09M | -$4.54M | -$5.26M | -$2.48M |
| EPS Diluted | -$0.18 | -$0.15 | -$0.22 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immix Biopharma, Inc. · CIK 1873835 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end
+2.2% from the close of May 7, 2026 to the close of May 8, 2026, the first after the release.